Abstract:Autophagy deficiency in macrophages exacerbates inflammation in atherosclerosis (AS) and recently, galectin‐3 (Gal‐3) has been implicated as a critical promoter of inflammation in AS. Further, melatonin (Mel) exerts anti‐inflammatory and antioxidant effects. However, it is unclear whether it regulates Gal‐3 to promote autophagy and reduce inflammation in AS. Therefore, in this study, we aimed to investigate whether Mel inhibits AS progression by downregulating Gal‐3 to enhance autophagy and inhibit inflammation. Thus, we performed in vivo and in vitro experiments using high‐fat diet (HFD)‐fed ApoE‐/‐ mice and THP‐1 macrophages, respectively. Smart‐seq of AS plaque macrophages revealed that the differentially expressed genes (DEGs) downregulated by Mel were enriched in immune‐related processes, and changes in inflammation status were confirmed based on lower levels of pro‐inflammatory factors in Mel‐treated HFD‐fed ApoE‐/‐ mice and THP‐1 macrophages. Further, via transcriptome‐based multi‐scale network pharmacology platform (TMNP), the upstream target genes of the Smart‐seq DEGs were identified, and Gal‐3 showed a high score. Gal‐3 was downregulated both in vivo and in vitro by Mel treatment, and the enrichment of the target genes predicted via the TMNP method indicated that autophagy considerably affected the DEGs. Mel treatment as well as Gal‐3 knockdown downregulated most inflammatory response‐related proteins, thereby enhancing autophagy and lowering inflammation. Mechanistically, Mel treatment inhibited Gal‐3 by lowering the activity of the nuclear transcription factor‐kappa B (NF‐κB) pathway, and promoting the nuclear localization of transcription factor EB (TFEB). However, increased secretion of CD98‐bound Gal‐3 activated the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) pathway and impaired autophagy. Thus, Mel promoted autophagy and restrained inflammation by downregulating Gal‐3, implying that it holds promise as treatment for AS.This article is protected by copyright. All rights reserved.

Melatonin ameliorates atherosclerosis by suppressing S100a9-mediated vascular inflammation

Melatonin Ameliorates the Progression of Atherosclerosis Via Mitophagy Activation and NLRP3 Inflammasome Inhibition

Melatonin Enhances Atherosclerotic Plaque Stability By Inducing Prolyl-4-Hydroxylase Alpha 1 Expression

Melatonin Ameliorates Atherosclerotic Plaque Vulnerability by Regulating PPARδ-Associated Smooth Muscle Cell Phenotypic Switching

Melatonin Protects Against Thoracic Aortic Aneurysm and Dissection Through SIRT1-dependent Regulation of Oxidative Stress and Vascular Smooth Muscle Cell Loss.

Melatonin attenuates smoking-induced atherosclerosis by activating the Nrf2 pathway via NLRP3 inflammasomes in endothelial cells

Melatonin inhibits atherosclerosis progression via Galectin‐3 downregulation to enhance autophagy and inhibit inflammation

Preventive and therapeutic effects of melatonin on rat fatty liver induced by high fat feeding

Melatonin inhibits the formation of intraplaque neovessels in ApoE-/- mice via PPARγ- RhoA-ROCK pathway

Melatonin Prevents Endothelial Dysfunction in SLE by Activating the Nuclear Receptor Retinoic Acid-Related Orphan Receptor-Α.

Melatonin-based Therapeutics for Atherosclerotic Lesions and Beyond: Focusing on Macrophage Mitophagy.

Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction

Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-κB, c/EBPβ, and p300 signaling

Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia‐reperfusion injury by improving mitochondrial quality control: Role of SIRT6

Melatonin Inhibits Inflammasome-Associated Activation of Endothelium and Macrophages Attenuating Pulmonary Arterial Hypertension

Melatonin suppresses atherosclerosis by ferroptosis inhibition via activating NRF2 pathway

Melatonin alleviates pyroptosis by regulating the SIRT3/FOXO3α/ROS axis and interacting with apoptosis in Atherosclerosis progression

The Potential of Melatonin to Treat Atherosclerosis by Targeting Mitochondria

Melatonin Safeguards Against Fatty Liver by Antagonizing TRAFs‐mediated ASK1 Deubiquitination and Stabilization in a Β‐arrestin‐1 Dependent Manner

Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR‐141‐mediated NLRP3 inflammasome and TGF‐β1/Smads signaling in diabetic cardiomyopathy

Melatonin Attenuates Diabetic Myocardial Microvascular Injury through Activating the AMPK/SIRT1 Signaling Pathway